Subscribe To
CEMI / Chembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Call Transcript
CEMI News
By Seeking Alpha
November 6, 2022
Chembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Call Transcript
Chembio Diagnostics, Inc. (NASDAQ:CEMI ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Re more_horizontal
By Seeking Alpha
August 7, 2022
Chembio Diagnostics, Inc.'s (CEMI) CEO Rick Eberly on Q2 2022 Results - Earnings Call Transcript
Chembio Diagnostics, Inc. (NASDAQ:CEMI ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Rela more_horizontal
By Seeking Alpha
May 8, 2022
Chembio Diagnostics, Inc. (CEMI) CEO Rick Eberly on Q1 2022 Results - Earnings Call Transcript
Chembio Diagnostics, Inc. (NASDAQ:CEMI ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Rick Eberly - President & Chief more_horizontal
By Seeking Alpha
March 3, 2022
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q4 2021 Results - Earnings Call Transcript
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Seeking Alpha
March 3, 2022
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q4 2021 Results - Earnings Call Transcript
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Seeking Alpha
March 3, 2022
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q4 2021 Results - Earnings Call Transcript
Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Benzinga
December 8, 2021
FDA Asks Chembio Additional Data On HIV-Syphilis Test For CLIA Waiver
Chembio Diagnostics Inc's (NASDAQ: CEMI) said that on December 1, it received an FDA notice for additional data related to Clinical Laboratory Improv more_horizontal
By Benzinga
December 8, 2021
FDA Asks Chembio Additional Data On HIV-Syphilis Test For CLIA Waiver
Chembio Diagnostics Inc's (NASDAQ: CEMI) said that on December 1, it received an FDA notice for additional data related to Clinical Laboratory Improv more_horizontal